glp 1 drugs heart failure Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit GLP-1RA in Different HFpEF Phenotypes

Slower titration improves tolerability at the cost of delayed maximum efficacy

and device manufacturers such as Nemera (Astorg/Montagu)

EMA (2019) First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

doi:10.31080/asne.2024.07.0731 Al-Massadi O, Fern J, Diguez C, Nogueiras R, Quiones M

These trials also demonstrated a significant reduction in C-Reactive Protein (CRP) levels, reinforcing the hypothesis that suppressing the pro-inflammatory state may yield substantial clinical benefits in this patient population

Srensen G, Reddy IA, Weikop P, Graham DL, Stanwood GD, Wortwein G, et al